Milestone’s Etripamil Shows Promise in Self-Managed PSVT Treatment
Company Announcements

Milestone’s Etripamil Shows Promise in Self-Managed PSVT Treatment

Milestone Pharmaceuticals (MIST) has released an update.

Milestone Pharmaceuticals reveals encouraging results from a Phase 3 study, showing that their investigational drug etripamil enables patients to self-manage recurrent paroxysmal supraventricular tachycardia (PSVT). The study, which was presented at The American College of Cardiology meeting and published in the Journal of the American College of Cardiology, found that etripamil effectively restored sinus rhythm with a median time of 17 minutes and had a well-tolerated safety profile. These findings suggest etripamil, as a self-administered nasal spray, could revolutionize the acute treatment of PSVT.

For further insights into MIST stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyMilestone partner announces Phase 3 study of etripamil met primary endpoint
TipRanks Auto-Generated NewsdeskMilestone Pharmaceuticals Welcomes New Directors and Auditor
TheFlyMilestone Pharmaceuticals appoints Joseph Papa to board of directors
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App